Readystate Asset Management LP Invests $5.94 Million in Nektar Therapeutics $NKTR

Readystate Asset Management LP acquired a new stake in Nektar Therapeutics (NASDAQ:NKTR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 85,110 shares of the biopharmaceutical company’s stock, valued at approximately $5,942,000. Readystate Asset Management LP owned about 0.25% of Nektar Therapeutics at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. BNP Paribas Financial Markets increased its stake in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares during the last quarter. KBC Group NV acquired a new stake in Nektar Therapeutics in the 1st quarter valued at about $52,000. Headlands Technologies LLC bought a new position in Nektar Therapeutics during the second quarter worth about $65,000. State of Wyoming bought a new position in Nektar Therapeutics during the first quarter worth about $67,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Nektar Therapeutics during the first quarter worth approximately $68,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics News Roundup

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Zacks raised its estimated 2026 loss to $8.58 per share from $10.59, including improved forecasts for third-quarter 2026 ($2.45 loss versus $3.05 previously) and fourth-quarter 2026 ($3.07 loss versus $3.26 previously). Nektar Therapeutics analyst estimates
• Positive Sentiment: The firm also modestly improved its first-quarter 2027 EPS estimate to a $3.17 loss from a $3.41 loss, suggesting some expected improvement in selected periods.
• Neutral Sentiment: Despite the revisions, Nektar remains expected to report substantial losses: the current consensus for the company’s full-year earnings is a loss of $8.51 per share, while the stock’s negative earnings profile underscores its dependence on clinical and pipeline progress rather than current profitability.
• Negative Sentiment: Zacks sharply reduced its 2027 outlook, increasing the projected full-year loss to $16.15 per share from $13.28. Estimates were also lowered for the second quarter of 2027, third quarter of 2027, and fourth quarter of 2027.
• Negative Sentiment: Longer-term expectations deteriorated further: the projected 2028 loss widened to $17.77 per share from $14.02, with estimates lowered for the first and second quarters of 2028 as well as the second quarter of 2028. These revisions imply greater anticipated cash burn or operating costs and are likely weighing on investor sentiment.

Insiders Place Their Bets

In other news, CEO Howard W. Robin sold 10,000 shares of Nektar Therapeutics stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.32, for a total transaction of $603,200.00. Following the completion of the sale, the chief executive officer owned 65,045 shares of the company’s stock, valued at approximately $3,923,514.40. This trade represents a 13.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jonathan Zalevsky sold 5,681 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total transaction of $397,670.00. Following the completion of the sale, the insider directly owned 9,756 shares of the company’s stock, valued at approximately $682,920. The trade was a 36.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 21,823 shares of company stock worth $1,380,558. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

NKTR has been the topic of several research analyst reports. Canaccord Genuity Group initiated coverage on Nektar Therapeutics in a research note on Wednesday, July 22nd. They issued a “buy” rating and a $153.00 price objective on the stock. JPMorgan Chase & Co. started coverage on Nektar Therapeutics in a report on Friday, August 21st. They set a “neutral” rating and a $65.00 target price on the stock. Wedbush dropped their price target on Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Friday, August 28th. Finally, TD Cowen raised shares of Nektar Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Nektar Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $141.50.

Nektar Therapeutics Price Performance

Shares of NKTR stock opened at $74.19 on Monday. The firm has a 50 day moving average price of $71.81 and a two-hundred day moving average price of $72.09. The company has a market capitalization of $2.53 billion, a PE ratio of -11.07 and a beta of 1.14. Nektar Therapeutics has a 12-month low of $33.40 and a 12-month high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) EPS for the quarter, beating the consensus estimate of ($1.97) by $0.74. The company had revenue of $10.13 million for the quarter, compared to the consensus estimate of $10.43 million. Nektar Therapeutics had a negative return on equity of 37.87% and a negative net margin of 287.84%. As a group, research analysts expect that Nektar Therapeutics will post -8.28 EPS for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.